HUGE is working out its new levels of Support and Resistance after a massive breakout.
FSD Pharma's front runner candidate, Lucid MS has recently begun its first round of clinical trials on a human subject.
Future projections of this security rely very heavily on the success of these clinical trials. If all goes well, the stock also has a massive potential for more upswing given how undersold it has become over the past 4 years
FSD Pharma's front runner candidate, Lucid MS has recently begun its first round of clinical trials on a human subject.
Future projections of this security rely very heavily on the success of these clinical trials. If all goes well, the stock also has a massive potential for more upswing given how undersold it has become over the past 4 years
Kommentar:
Looks like we did experience a follow through after marking off a bearish head and shoulders pattern. RSI had also indicated we needed to cool off a bit. This comes in as the company receives 2.8 billion in arbitration costs from another case.